Date: February 15, 2022
Time: 7:00pm-8:00pm (EST)
Speakers: Dr. Chelsie Rohrscheib (Ph.D)
The CDC estimates that approximately 20% of the population has some form of obstructive sleep apnea and a large proportion of this population are individuals with mild to moderate OSA that have never been screened or were misdiagnosed. Modern OSA screening techniques have several pitfalls that keep individuals with mild OSA from getting the therapy that they need. This discussion will focus on why individuals with mild OSA are more likely to never receive treatment and how emerging screening techniques will improve future diagnostic and treatment rates.
Speaker & Bio:
Dr. Chelsie Rohrscheib (Ph.D) is the head sleep expert and neuroscientist at Wesper, an at-home sleep technology company that aims to make screening for common sleep disorders, like sleep apnea, easier and more accessible. Prior to joining Wesper, Chelsie specialized in sleep research where she evaluated the molecular mechanisms that control sleep in the brain and how sleep loss affects health. Following her research career, Chelsie oversaw clinical trials evaluating treatments for obstructive sleep apnea. Chelsie is passionate about educating the public on topics related to sleep health and sleep disorders, and enjoys working with Wesper users to help them navigate their sleep improvement journey.